{"id":33156,"date":"2023-01-18T10:25:32","date_gmt":"2023-01-18T05:25:32","guid":{"rendered":"http:\/\/myanmarnewsgazette.com\/?guid=fff039610fc20346277f4312f286b1a3"},"modified":"2023-01-18T10:25:32","modified_gmt":"2023-01-18T05:25:32","slug":"junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china","status":"publish","type":"post","link":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/","title":{"rendered":"Junshi Biosciences Announces Acceptance of NDA for VV116 in China"},"content":{"rendered":"
\n

SHANGHAI, China, Jan. 17, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the new drug application (\u201cNDA\u201d) for Deuremidevir Hydrobromide Tablets (project code: JT001\/VV116, \u201cVV116\u201d), an oral nucleoside analog anti-SARS-CoV-2 drug, has been accepted by the National Medical Products Administration (the \u201cNMPA\u201d) for the treatment of the coronavirus disease 2019 (\u201cCOVID-19\u201d).<\/p>\n

About Junshi Biosciences<\/strong>
\nFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib\/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in\u00a0China\u00a0to be approved for clinical trials by the NMPA.<\/p>\n

In the face of the pandemic, Junshi Biosciences\u2019 response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China\u2019s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the\u00a0Institute of Microbiology of the Chinese Academy\u00a0of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. As of December 3 2021, over 700,000 patients have been treated with bamlanivimab or bamlanivimab and etesevimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. The JS016 and VV116 programs are a part of the company\u2019s continuous innovation for disease control and prevention of the global pandemic.<\/p>\n

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http:\/\/junshipharma.com<\/a>.<\/p>\n

Junshi Biosciences Contact Information<\/strong>
\nIR Team:
\nJunshi Biosciences
\ninfo@junshipharma.com<\/a>
\n+ 86 021-6105 8800<\/p>\n

PR Team:
\nJunshi Biosciences
\nZhi Li
\nzhi_li@junshipharma.com<\/a>
\n+ 86 021-6105 8800<\/p>\n

GlobeNewswire Distribution ID 8731749<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SHANGHAI, China, Jan. 17, 2023 (GLOBE NEWSWIRE) \u2014 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the new drug application (\u201cNDA\u201d) for Deuremidevir Hydrobromide Tablets (project code: JT001\/VV116, \u201cVV116\u201d), an oral nucleoside analog anti-SARS-CoV-2 [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"yoast_head":"\nJunshi Biosciences Announces Acceptance of NDA for VV116 in China - Myanmar News Gazette<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Acceptance of NDA for VV116 in China - Myanmar News Gazette\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, Jan. 17, 2023 (GLOBE NEWSWIRE) \u2014 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the new drug application (\u201cNDA\u201d) for Deuremidevir Hydrobromide Tablets (project code: JT001\/VV116, \u201cVV116\u201d), an oral nucleoside analog anti-SARS-CoV-2 [\u2026]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/\" \/>\n<meta property=\"og:site_name\" content=\"Myanmar News Gazette\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-18T05:25:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ci3.googleusercontent.com\/proxy\/dRxM2C5PGh-5vd5-nvXgweZBNXH2HbNVDAMQJelxTV59H2U0aXsY962k81W18tqy_ICKYK9Gp9cfNvLnBT65bKZeCP5gRcGEPiuPxI2TM4CtRYFkggnP7anpEsfTRDo3qXCXfwdniFm74MSa-O78gnsJA8kyXUBlPzOFUFyUMi2SppxhR9J9Rp9YY_C7tA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/ZWMyYTc2ZWQtMzg4Mi00ODIxLTkxMzQtMWI3NjlhMjdhOWFhLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f\"},\"headline\":\"Junshi Biosciences Announces Acceptance of NDA for VV116 in China\",\"datePublished\":\"2023-01-18T05:25:32+00:00\",\"dateModified\":\"2023-01-18T05:25:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/\"},\"wordCount\":444,\"publisher\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ci3.googleusercontent.com\/proxy\/dRxM2C5PGh-5vd5-nvXgweZBNXH2HbNVDAMQJelxTV59H2U0aXsY962k81W18tqy_ICKYK9Gp9cfNvLnBT65bKZeCP5gRcGEPiuPxI2TM4CtRYFkggnP7anpEsfTRDo3qXCXfwdniFm74MSa-O78gnsJA8kyXUBlPzOFUFyUMi2SppxhR9J9Rp9YY_C7tA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/ZWMyYTc2ZWQtMzg4Mi00ODIxLTkxMzQtMWI3NjlhMjdhOWFhLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png\",\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/\",\"url\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/\",\"name\":\"Junshi Biosciences Announces Acceptance of NDA for VV116 in China - Myanmar News Gazette\",\"isPartOf\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ci3.googleusercontent.com\/proxy\/dRxM2C5PGh-5vd5-nvXgweZBNXH2HbNVDAMQJelxTV59H2U0aXsY962k81W18tqy_ICKYK9Gp9cfNvLnBT65bKZeCP5gRcGEPiuPxI2TM4CtRYFkggnP7anpEsfTRDo3qXCXfwdniFm74MSa-O78gnsJA8kyXUBlPzOFUFyUMi2SppxhR9J9Rp9YY_C7tA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/ZWMyYTc2ZWQtMzg4Mi00ODIxLTkxMzQtMWI3NjlhMjdhOWFhLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png\",\"datePublished\":\"2023-01-18T05:25:32+00:00\",\"dateModified\":\"2023-01-18T05:25:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/#primaryimage\",\"url\":\"https:\/\/ci3.googleusercontent.com\/proxy\/dRxM2C5PGh-5vd5-nvXgweZBNXH2HbNVDAMQJelxTV59H2U0aXsY962k81W18tqy_ICKYK9Gp9cfNvLnBT65bKZeCP5gRcGEPiuPxI2TM4CtRYFkggnP7anpEsfTRDo3qXCXfwdniFm74MSa-O78gnsJA8kyXUBlPzOFUFyUMi2SppxhR9J9Rp9YY_C7tA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/ZWMyYTc2ZWQtMzg4Mi00ODIxLTkxMzQtMWI3NjlhMjdhOWFhLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png\",\"contentUrl\":\"https:\/\/ci3.googleusercontent.com\/proxy\/dRxM2C5PGh-5vd5-nvXgweZBNXH2HbNVDAMQJelxTV59H2U0aXsY962k81W18tqy_ICKYK9Gp9cfNvLnBT65bKZeCP5gRcGEPiuPxI2TM4CtRYFkggnP7anpEsfTRDo3qXCXfwdniFm74MSa-O78gnsJA8kyXUBlPzOFUFyUMi2SppxhR9J9Rp9YY_C7tA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/ZWMyYTc2ZWQtMzg4Mi00ODIxLTkxMzQtMWI3NjlhMjdhOWFhLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/myanmarnewsgazette.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Junshi Biosciences Announces Acceptance of NDA for VV116 in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#website\",\"url\":\"https:\/\/myanmarnewsgazette.com\/\",\"name\":\"Myanmar News Gazette\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/myanmarnewsgazette.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#organization\",\"name\":\"Myanmar News Gazette\",\"url\":\"https:\/\/myanmarnewsgazette.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png\",\"contentUrl\":\"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png\",\"width\":200,\"height\":200,\"caption\":\"Myanmar News Gazette\"},\"image\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/myanmarnewsgazette.com\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Acceptance of NDA for VV116 in China - Myanmar News Gazette","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Acceptance of NDA for VV116 in China - Myanmar News Gazette","og_description":"SHANGHAI, China, Jan. 17, 2023 (GLOBE NEWSWIRE) \u2014 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the new drug application (\u201cNDA\u201d) for Deuremidevir Hydrobromide Tablets (project code: JT001\/VV116, \u201cVV116\u201d), an oral nucleoside analog anti-SARS-CoV-2 [\u2026]","og_url":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/","og_site_name":"Myanmar News Gazette","article_published_time":"2023-01-18T05:25:32+00:00","og_image":[{"url":"https:\/\/ci3.googleusercontent.com\/proxy\/dRxM2C5PGh-5vd5-nvXgweZBNXH2HbNVDAMQJelxTV59H2U0aXsY962k81W18tqy_ICKYK9Gp9cfNvLnBT65bKZeCP5gRcGEPiuPxI2TM4CtRYFkggnP7anpEsfTRDo3qXCXfwdniFm74MSa-O78gnsJA8kyXUBlPzOFUFyUMi2SppxhR9J9Rp9YY_C7tA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/ZWMyYTc2ZWQtMzg4Mi00ODIxLTkxMzQtMWI3NjlhMjdhOWFhLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/#article","isPartOf":{"@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/"},"author":{"name":"admin","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f"},"headline":"Junshi Biosciences Announces Acceptance of NDA for VV116 in China","datePublished":"2023-01-18T05:25:32+00:00","dateModified":"2023-01-18T05:25:32+00:00","mainEntityOfPage":{"@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/"},"wordCount":444,"publisher":{"@id":"https:\/\/myanmarnewsgazette.com\/#organization"},"image":{"@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/#primaryimage"},"thumbnailUrl":"https:\/\/ci3.googleusercontent.com\/proxy\/dRxM2C5PGh-5vd5-nvXgweZBNXH2HbNVDAMQJelxTV59H2U0aXsY962k81W18tqy_ICKYK9Gp9cfNvLnBT65bKZeCP5gRcGEPiuPxI2TM4CtRYFkggnP7anpEsfTRDo3qXCXfwdniFm74MSa-O78gnsJA8kyXUBlPzOFUFyUMi2SppxhR9J9Rp9YY_C7tA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/ZWMyYTc2ZWQtMzg4Mi00ODIxLTkxMzQtMWI3NjlhMjdhOWFhLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png","articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/","url":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/","name":"Junshi Biosciences Announces Acceptance of NDA for VV116 in China - Myanmar News Gazette","isPartOf":{"@id":"https:\/\/myanmarnewsgazette.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/#primaryimage"},"image":{"@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/#primaryimage"},"thumbnailUrl":"https:\/\/ci3.googleusercontent.com\/proxy\/dRxM2C5PGh-5vd5-nvXgweZBNXH2HbNVDAMQJelxTV59H2U0aXsY962k81W18tqy_ICKYK9Gp9cfNvLnBT65bKZeCP5gRcGEPiuPxI2TM4CtRYFkggnP7anpEsfTRDo3qXCXfwdniFm74MSa-O78gnsJA8kyXUBlPzOFUFyUMi2SppxhR9J9Rp9YY_C7tA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/ZWMyYTc2ZWQtMzg4Mi00ODIxLTkxMzQtMWI3NjlhMjdhOWFhLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png","datePublished":"2023-01-18T05:25:32+00:00","dateModified":"2023-01-18T05:25:32+00:00","breadcrumb":{"@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/#primaryimage","url":"https:\/\/ci3.googleusercontent.com\/proxy\/dRxM2C5PGh-5vd5-nvXgweZBNXH2HbNVDAMQJelxTV59H2U0aXsY962k81W18tqy_ICKYK9Gp9cfNvLnBT65bKZeCP5gRcGEPiuPxI2TM4CtRYFkggnP7anpEsfTRDo3qXCXfwdniFm74MSa-O78gnsJA8kyXUBlPzOFUFyUMi2SppxhR9J9Rp9YY_C7tA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/ZWMyYTc2ZWQtMzg4Mi00ODIxLTkxMzQtMWI3NjlhMjdhOWFhLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png","contentUrl":"https:\/\/ci3.googleusercontent.com\/proxy\/dRxM2C5PGh-5vd5-nvXgweZBNXH2HbNVDAMQJelxTV59H2U0aXsY962k81W18tqy_ICKYK9Gp9cfNvLnBT65bKZeCP5gRcGEPiuPxI2TM4CtRYFkggnP7anpEsfTRDo3qXCXfwdniFm74MSa-O78gnsJA8kyXUBlPzOFUFyUMi2SppxhR9J9Rp9YY_C7tA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/ZWMyYTc2ZWQtMzg4Mi00ODIxLTkxMzQtMWI3NjlhMjdhOWFhLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png"},{"@type":"BreadcrumbList","@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-acceptance-of-nda-for-vv116-in-china\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/myanmarnewsgazette.com\/"},{"@type":"ListItem","position":2,"name":"Junshi Biosciences Announces Acceptance of NDA for VV116 in China"}]},{"@type":"WebSite","@id":"https:\/\/myanmarnewsgazette.com\/#website","url":"https:\/\/myanmarnewsgazette.com\/","name":"Myanmar News Gazette","description":"","publisher":{"@id":"https:\/\/myanmarnewsgazette.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/myanmarnewsgazette.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/myanmarnewsgazette.com\/#organization","name":"Myanmar News Gazette","url":"https:\/\/myanmarnewsgazette.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/","url":"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png","contentUrl":"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png","width":200,"height":200,"caption":"Myanmar News Gazette"},"image":{"@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/myanmarnewsgazette.com\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/posts\/33156"}],"collection":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/comments?post=33156"}],"version-history":[{"count":0,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/posts\/33156\/revisions"}],"wp:attachment":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/media?parent=33156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/categories?post=33156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/tags?post=33156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}